New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva announced discrete choice experiment data showing that 489 healthcare providers ranked somnolence risk and short-term symptom improvement as the top attributes when selecting a VMAT2 inhibitor for tardive dyskinesia in patients aged 55 and older, with AUSTEDO showing the highest predicted choice probability across all four patient profiles. The data, presented at Psych Congress (September 15-19, 2026, New Orleans), quantified decision weights: somnolence risk carried 26.8%-36.2% of decision weight, short-term AIMS improvement 24.4%-29.5%, dose formulation 16.7%-20.2%, and drug-drug interaction risk 14.4%-17.3%.
Key figures
- Hcp survey count
- 489
- Dose formulation weight
- 16.7%-20.2%
- Registry followup months
- 24
- Somnolence decision weight
- 26.8%-36.2%
- Drug drug interaction weight
- 14.4%-17.3%
- Untreated td stable or worsening
- 55%-69%
- Untreated td mild or greater impact
- 89%-96%
- Untreated td moderate severe impact
- 60%-74%
- Short term symptom improvement weight
- 24.4%-29.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.